Low gastrin-releasing peptide precursor is generally not considered lung cancer.
Gastrin-releasing peptide precursor mainly exists in the gastrointestinal tract, respiratory tract and central nervous system, and is often used as a tumor marker for small-cell lung cancer, which is highly specific, and commonly used in the early auxiliary diagnosis of small-cell lung cancer, monitoring of the condition, evaluation of treatment efficacy and prognosis judgment in the clinic.
In general, the normal value of this index is <46ng/L, if it is greater than 46ng/L, it suggests the possibility of lung cancer. Besides, tumor marker can only be used as a means of screening, and cannot be used as a basis for definitive diagnosis, therefore, it needs to be combined with the lung imaging examination such as lung CT, PET-CT and so on to assist in diagnosis, and the final diagnosis of lung cancer needs to be made by taking biopsy of pathological tissues, which is the gold standard for diagnosis. A low level of gastrin-releasing peptide precursor is generally not a cause for concern. If the value is high, it indicates the possibility of tumor or cancer. It is necessary to go to the regular hospital for further examination in time to clarify the cause of the disease and have targeted treatment.